U-33030 |
HALCION |
KENTION |
TRIAZOLAM CIV |
TRIAZOLAM |
N05CD05 |
TRIAZOLAMUM |
pubchem.compound:5556 |
chembl:CHEMBL646 |
drugbank:00897 |
rxcui:10767 |
chemidplus:28911-01-5 |
Year of Approval | 1982 |
Drug Class | hypnotics and sedatives |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | analgesic,sedative |
Drug Groups | investigational |
Drug Categories | agents causing muscle toxicity |
Drug Categories | benzodiazepine hypnotics and sedatives |
Drug Categories | benzodiazepines and benzodiazepine derivatives |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 cyp3a7 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | drugs that are mainly renally excreted |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | triazolobenzodiazepines |
potentiator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Novel drug target | Established target |
potentiator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Novel drug target | Established target |
potentiator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Novel drug target | Established target |
positive modulator (activating) |
potentiator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
positive modulator (activating) |
potentiator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Novel drug target | Established target |
Direct Interaction | yes |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
positive modulator (activating) |
potentiator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
positive modulator (activating) |
potentiator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Novel drug target | Established target |
Direct Interaction | yes |
positive modulator (activating) |
allosteric modulator |
potentiator |
Novel drug target | Established target |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
ligand |
positive modulator (activating) |
allosteric modulator |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
positive modulator (activating) |
potentiator |
Novel drug target | Established target |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
positive modulator (activating) |
allosteric modulator |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
positive modulator (activating) |
allosteric modulator |
potentiator |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
Novel drug target | Established target |
Direct Interaction? | True |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
TRIAZOLAM | DrugBank Drug Name |
28911-01-5 | CAS Number |
Alti-triazolam Tab 0.125mg | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
TRIAZOLAM | Primary Drug Name |
Drug Class | hypnotics and sedatives |
Year of Approval | 1982 |
Drug Indications | analgesic,sedative |
Drug Class | Small Molecule |
FDA Approval | approved |
CHEMBL646 | ChEMBL Drug ID |
TRIAZOLAM | GuideToPharmacology Ligand Name |
D0U3LS | TTD Drug ID |